Matches 1 - 50 out of 172 1 2 3 4 >


Match Document Document Title
US20150203477 COMPOUNDS AND METHODS FOR ACTIVATING THE APOPTOTIC ARM OF THE UNFOLDED PROTEIN RESPONSE  
N-substituted sulfonylphenyl-5-nitrofuranyl-2-carboxamide derived compounds, which selectively activate the apoptotic, but not the adaptive arm, of the Unfolded Protein Response are provides as is...
US20120302561 Compounds, Formulations, and Methods of Protein Kinase C Inhibition  
The invention provides a method of inhibiting atypical protein kinase C (aPKC) comprising contacting an aPKC with a compound having a structure selected from the group consisting of structural...
US20120003228 METHODS FOR PREDICTING AUTOIMMUNE DISEASE RISK  
The invention relates to means and methods for determining whether a subject is at high or low risk of autoimmune disease progression by determining the CD8 or CD4 cell subtype of the subject....
US20140121193 METHODS FOR TREATING FIBROMYALGIA  
The invention provides methods for treating or ameliorating cognitive dysfunction, fatigue, energy, concentration, mood, and pain associated with fibromyalgia using compositions containing...
US20150025068 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER  
A compound of formula (I), useful for the treatment of cancer, inflammation and inflammatory disorders, and a pharmaceutical composition containing the compound.
US20140005181 SMALL MOLECULE ANTAGONISTS OF THE APELIN RECEPTOR FOR THE TREATMENT OF DISEASE  
The present disclosure relates to compounds and methods for treating a disease mediated by apelin.
US20110117055 Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds  
Provided herein are hepatitis C virus entry inhibitor oxoacetamide compounds, pharmaceutical compositions thereof, and methods for their use in treatment or prevention of hepatitis C virus...
US20150133442 METHODS AND COMPOSITIONS FOR THE INHIBITION OF PIN1  
The invention features compositions and methods for inhibiting the Pin1 protein, and the treatment of disorders characterized by elevated Pin1 levels.
US20140072536 METHODS OF TREATING MUSCULAR DYSTROPHY  
Disclosed herein are α7β1 integrin modulatory agents and methods of using such to treat conditions associated with decreased α7β1 integrin expression or activity, including muscular dystrophy. In...
US20110281853 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING ATRIAL FIBRILLATION  
The present invention provides compositions and methods for treating or preventing atrial fibrillation (AF). In particular, the present invention provides administration of muscarinic receptor...
US20110275626 FORMULATION FOR ORAL TRANSMUCOSAL ADMINISTRATION OF ANALGESIC AND/OR ANTISPASMODIC MOLECULES  
A formulation for oral transmucosal administration of at least one active principle with antispasmodic and/or analgesic effect, including the active principle in base form and/or in salt form, an...
US20110009353 TARGETING CDK4 AND CDK6 IN CANCER THERAPY  
The invention involves methods of inhibiting the cancer cell cycle to make cancer cells more susceptible to chemotherapeutic agents. In particular, inhibition of CDK4 and/or CDK6 inhibits cell...
US20130123253 MODULATORS OF CENTRAL NERVOUS SYSTEM NEUROTRANSMITTERS  
Disclosed are agents having pharmacological activity against cellular receptors and intracellular signaling, particularly receptors and signaling pathways of central nervous system (CNS)...
US20120164103 Compounds and Methods for the Treatment or Prevention of Flavivirus Infections  
Compounds represented by formula I: or pharmaceutically acceptable salts and solvates thereof, wherein R1, X, Y, Y1, and Z are as defined herein, are useful for treating flaviviridae viral infections.
US20120004219 Method of Inhibition of Respiratory Depression Using Positive Allosteric AMPA Receptor Modulators  
The invention is directed to a method for alleviating respiratory depression in a subject as a result of disease of pharmacological agents such as opiates, opioids or barbiturates. The invention...
US20110104162 Compounds which can be used for the Treatment of Cancers  
The present invention relates to a compound of general formula (I): and also to the pharmaceutically acceptable salts thereof, to the isomers or isomer mixtures thereof in all proportions, in...
US20120245166 TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH  
Methods for enhancing memory and/or learning and prevent neurodegeneration by administration of certain heterocyclic and aromatic compounds are described. The methods are particularly useful for...
US20140309208 DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES  
Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds are disclosed that are represented by general formula (I). Also disclosed, are pharmaceutical compositions including these compounds and...
US20090286781 Use of Suluble Guanylate Cyclase Acitvators for Treating Acute and Chronic Lung Diseases  
The present invention relates to the use of compounds of the formulae I-VI for manufacturing a pharmaceutical for the treatment of acute and chronic lung disorders such as the respiratory distress...
US20150239859 PERIPHERALLY-ACTING CANNABINOID RECEPTOR AGONISTS FOR CHRONIC PAIN  
Peripherally acting cannabinoid agonist compounds, pharmaceutical compositions, and methods of using them are presented.
US20120004225 BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE  
The present invention provides bumetanide, furosemide, piretanide, azosemide, and torsemide analogs and compositions comprising such analogs. The present invention also provides pharmaceutical...
US20130281452 SUBSTITUTED 4-AMINOBENZAMIDES AS KCNQ2/3 MODULATORS  
Substituted 4-aminobenzamides, pharmaceutical compositions containing these compounds and also methods of using these compounds in the treatment and/or prophylaxis of pain and further diseases...
US20130040945 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS  
Chemical entities that are arctigenin derivatives, pharmaceutical compositions and methods of treatment of cancer are described.
US20120184545 HEART-SLOWING DRUG CONTAINING SHORT-ACTING BETA-BLOCKER AS TEH ACTIVE INGREDIENT  
The present invention relates to an agent which slows down the heart rate which has an excellent controlling ability in diagnostic imaging comprising a short-acting β-blocker (e.g. landiolol...
US20140073501 ISOLATED BACTERIAL STRAIN OF THE GENUS BURKHOLDERIA AND PESTICIDAL METABOLITES THEREFROM  
A species of Burkholderia sp with no known pathogenicity to vertebrates but with pesticidal activity (e.g., plants, insects, fungi, weeds and nematodes) is provided. Also provided are natural...
US20080279866 Induction of immunosuppression by inhibition of ATM  
The present invention is directed to methods of inducing immunosuppression in a patient by administering an inhibitor of the enzyme Ataxia telangiectasia mutated (Atm). The method may be used as a...
US20130158028 USE OF STIMULATORS AND ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE FOR TREATING SICKLE-CELL ANEMIA AND CONSERVING BLOOD SUBSTITUTES  
The present invention relates to the novel use of stimulators and activators of soluble guanylate cyclase for the treatment of sickle cell anemia and for the preservation of blood substitutes. The...
US20090118269 Methods for Treating Spinal Muscular Atrophy Using Tetracycline Compounds  
Methods for using tetracycline compounds for the treatment of spinal muscular atrophy are described.
US20150252043 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES  
The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds...
US20130236434 AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS  
A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the...
US20120101080 COMPOSITION FOR TREATMENT OF TUBERCULOSIS  
The invention relates to a pharmaceutical composition comprising a compound of formula (1) wherein R1 is optionally substituted phenyl, optionally substituted pyridyl or optionally substituted...
US20150232945 IDENTIFICATION OF NOVEL PATHWAYS FOR DRUG DEVELOPMENT FOR LUNG DISEASE  
The invention provides the identification of oncogenic pathways activated in cytologically normal airway cells of individuals having or at risk of having lung disease, as well as specific gene...
US20090298822 Use of Activators of Soluble Guanylate Cyclase for Treating Reperfusion Damage  
The present invention relates to the use of compounds for manufacturing a pharmaceutical product/medicament for the prophylaxis and/or treatment of reperfusion damage.
US20060135515 Heterocyclic amides and their use treating thromboembolic diseases and tumors  
Novel compounds of the formula (I), in which D, W, X, Y, T and R1 have the meaning indicated in Patent Claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis...
US20080261967 Modulators of Central Nervous System Neurotransmitters  
Disclosed are agents having pharmacological activity against cellular receptors and intracellular signaling, particularly receptors and signaling pathways of central nervous system (CNS)...
US20080045523 Synthesis of Polyoxygenated Nitrogen Systems, Comprising Reactions Between Enamines of 1,3-Dioxan-5-Ones and Nitroolefins  
The invention relates to the synthesis of polyoxygenated nitrogen systems, comprising reactions between enamines of 1,3-dioxan-5-ones and nitroolefins. More specifically, the invention relates to...
US20110021505 Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain  
The present invention relates to the use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides of the formula I, wherein A and R1 to R6 have the meanings indicated in the claims, for...
US20150005275 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS.  
The present invention discloses compounds according to Formula I: wherein R1, R2, R3, L, and the subscript m are as defined herein. The present invention relates to compounds and their use in the...
US20120022059 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF  
The present invention relates to novel substituted furancarboxamides, methods for their production, their use for the treatment and/or prevention of diseases, as well as their use for the...
US20140038956 Use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc).  
The use of sGC stimulators, sGC activators alone, or in combination with PDE5 inhibitors for the prevention and treatment of fibrotic diseases, such as systemic sclerosis, scleroderma, and the...
US20140148448 INHIBITORS OF C-FMS KINASE  
The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts...
US20090186884 Diaminopropanol Renin Inhibitors  
Described are diaminopropanols of which are orally active and bind to renin to inhibit its activity. They are useful in the treatment or amelioration of diseases associated with elevated levels of...
US20100311738 Pharmaceutical Composition For The Parenteral Administration Of Ultrashort-Effective Beta-Adrenoreceptor Antagonists  
The present invention relates to a pharmaceutical composition in the form of a storage-stable solution for the parenteral administration of ultrashort-effective β-adrenoreceptor antagonists,...
US20090105240 Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same  
The present disclosure relates to methods for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome and acute myelogenous leukemia. The present disclosure further relates...
US20130184222 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE  
Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1 comprising administering to a subject in need thereof a compound described here.
US20130196994 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS  
Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological...
US20110224202 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS  
Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological...
US20070265257 Morpholine Compound  
A compound represented by the formula (1) wherein ring A is aryl optionally having substituent(s) and the like; ring B is arylene optionally having substituent(s) and the like; m=0-2; n=1-5; X is...
US20080234258 Dihydroxyanthraquinones and Their Use  
A compound of formula (1) wherein X is H or —OCR1 and Y is H or —OCR2, provided that X and Y are not both H; and R is CH2OR9, CONR11R12, CN, tetrazole or COOR17; or a salt thereof, has therapeutic...
US20150197530 USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES  
The present invention relates to a thiophene derivative of the following general formula I or an enantiomer, diastereoisomer, hydrate, solvate, tautomer, racemic mixture or pharmaceutically...

Matches 1 - 50 out of 172 1 2 3 4 >